Researchers make synthetic HDL cholesterol: study

By Julie Steenhuysen

CHICAGO (Reuters) - U.S. researchers have developed a synthetic form of good cholesterol known as HDL they hope will be able to keep levels of bad cholesterol in check.

The compound, which has a tiny core of gold, is manufactured using nanotechnology, and its developers think it has the potential to rid the body of excess bad cholesterol.

“The idea is you take this and effectively just urinate it out,” said Chad Mirkin of Northwestern University in Chicago, whose study was published on Monday in the Journal of the American Chemical Society.

Mirkin, director of Northwestern’s International Institute for Nanotechnology, said the molecule mirrors the size and structure of high-density lipoprotein, or HDL.

It is comprised of a carefully sized gold particle swathed in fat molecules known as lipids and capped off with a protein layer. It is designed to attract and trap low-density lipoprotein, or LDL, the bad kind of cholesterol that can build up in arteries and cause heart attacks and strokes.

Powerful drugs known as statins can help lower LDL levels, but they do little to raise levels of protective HDL cholesterol.

“The hope is this will be a material that doesn’t have side effects, that allows you to do what the statins don’t do. That is raise the HDL level, which might be able reverse a lot of the damage and plaques that are already there,” Mirkin said.

Current drugs that raise natural levels of HDL, such as niacin, cause unpleasant side effects such as flushing. And while many drug companies are working to develop better HDL-raising drugs, few have succeeded.

“HDL is a natural nanoparticle, and we’ve successfully mimicked it,” Mirkin said in a statement.

Mirkin said gold is an ideal scaffolding material because its shape can be easily tailored, and it is non-toxic, making it a good drug candidate.

“Gold is already used in therapies for arthritis and as contrast agent in imaging,” Mirkin said.

“From an FDA approval standpoint, we think the bar will be a lot lower than with other materials,” he said, referring to the U.S. Food and Drug Administration.

Mirkin is testing the synthetic HDL molecules in animals. “Will they bind to cholesterol and effectively lower cholesterol, and will they reverse the damage of plaques? That would be absolutely spectacular,” he said.

Analysts believe the market potential for HDL-raising drugs is well over $10 billion.

Current HDL-raising drugs include Abbott Laboratories Inc’s Niaspan, which also lowers a type of blood fat called triglycerides. In Europe, Merck & Co markets a drug called Tredaptive that combines niacin with an anti-flushing agent. The drug was rejected by U.S. health regulators.  Continued…


Related Posts:

By Will Dunham WASHINGTON (Reuters) - An obese child’s arteries may be just as clogged as the arteries of someone who is middle-aged, researchers said on Tuesday. This buildup of fatty plaque means the children may risk heart attack or stroke as early as age 30, according to Dr. Geetha Raghuveer of the University of Missouri Kansas

Full Post: Obese kids’ arteries look like middle-aged adults’

Lipitor is a prescription drug to treat high cholesterol. If you suffer from high cholesterol despite lowering your cholesterol intake, Lipitor can help return your cholesterol readings into a healthy range. This will reduce the stress on your arteries due to fat deposits and lower your risk for heart disease, heart attacks, and

Full Post: Lower Your Cholesterol with Lipitor

By Will Dunham WASHINGTON (Reuters) - Nearly 20 percent more U.S. men over 50 and women over 60 stand to benefit from taking statins, based on the findings of a recent study on the cholesterol-lowering drugs, U.S. researchers said on Tuesday. Their research stakes out a potentially expanded market for statins, already the world’s top-selling drugs. The so-called

Full Post: Statins may help millions more people: study

By Martha Kerr NEW ORLEANS (Reuters Health) - Levels of “bad” LDL cholesterol among adult Americans have fallen somewhat since 1980. However, harmful triglyceride levels have nearly quintupled over the same time period, according to research presented at the American Heart Association’s annual meeting. Research presenter Dr. Jerome D. Cohen of St. Louis University, Missouri, told Reuters Health

Full Post: Good news and bad on cholesterol levels: study

WASHINGTON (Reuters) - The American Medical Association threw its weight behind legislation to ban the use of artificial trans fats in restaurants and bakeries nationwide on Monday. The group, which represents about 240,000 doctors and medical students, said it would move away from a previous, gentler position that advised people to reduce their use and move

Full Post: AMA supports trans-fat bans

Site Navigation

Most Read